title: Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.
abstract: This study focuses on the co-engineering of salbutamol sulphate (SS), a common bronchodilator, and mannitol (MA), a mucolytic, as a potential combination therapy for mucus hypersecretion. This combination was chosen to have a synergic effect on the airways: the SS will act on the β2-receptor for relaxation of smooth muscle and enhancement of ciliary beat frequency, whilst mannitol will improve the fluidity of mucus, consequently enhancing its clearance from the lung. A series of co-spray-dried samples, containing therapeutically relevant doses of SS and MA, were prepared. The physico-chemical characteristics of the formulations were evaluated in terms of size distribution, morphology, thermal and moisture response and aerosol performance. Additionally, the formulations were evaluated for their effects on cell viability and transport across air interface Calu-3 bronchial epithelial cells, contractibility effects on bronchial smooth muscle cells and cilia beat activity using ciliated nasal epithelial cells in vitro. The formulations demonstrated size distributions and aerosol performance suitable for inhalation therapy. Transport studies revealed that the MA component of the formulation enhanced penetration of SS across the complex mucus layer and the lung epithelia cells. Furthermore, the formulation in the ratios of SS 10(-6) and MA 10(-3) M gave a significant increase in cilia beat frequency whilst simultaneously preventing smooth muscle contraction associated with mannitol administration. These studies have established that co-spray dried combination formulations of MA and SS can be successfully prepared with limited toxicity, good aerosol performance and the ability to increase ciliary beat frequency for improving the mucociliary clearance in patients suffering from hyper-secretory diseases, whilst simultaneously acting on the underlying smooth muscle.
authors.affiliation: Respiratory Technology, Woolcock Institute of Medical Research, 431 Glebe Point Road, Sydney, NSW, 2037, Australia.
authors.forename: Hui Xin
authors.initials: HX
authors.lastname: Ong
authors.forename: Daniela
authors.initials: D
authors.lastname: Traini
authors.forename: Giulia
authors.initials: G
authors.lastname: Ballerin
authors.forename: Lucy
authors.initials: L
authors.lastname: Morgan
authors.forename: Lachlan
authors.initials: L
authors.lastname: Buddle
authors.forename: Santo
authors.initials: S
authors.lastname: Scalia
authors.forename: Paul M
authors.initials: PM
authors.lastname: Young
mesh_terms: D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage* / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002478:Cells, Cultured; D002923:Cilia / Q000502:physiology; D004359:Drug Therapy, Combination; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000503:physiopathology*; D008353:Mannitol / Q000008:administration & dosage* / Q000627:therapeutic use; D008855:Microscopy, Electron, Scanning; D009093:Mucus / Q000378:metabolism*; D009130:Muscle, Smooth / Q000503:physiopathology
chemical_list: D001993:Bronchodilator Agents; D008353:Mannitol; D000420:Albuterol